AbbVie Secures Fourth FDA Approval for Vraylar
AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. According to AbbVie, the approval makes Vraylar (cariprazine) the "first and only" dopamine and serotonin partial agonist indicated as an add-on therapy for depression, adding to the growing list of options for patients who struggle to control their mood with standard antidepressants alone.
The term "responsibility" refers to the act of determining whether or not a person is responsible for the actions of anothe...
